Fidèle Sebera
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fidèle Sebera has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Dirk Edward Teuwen
Department of Neurology Ghent University Hospital Ghent Belgium
2 shared publications - Paul Boon
Brain, Department of Head and Skin, Ghent University, Ghent, Belgium
2 shared publications - Peter Dedeken
Department of Neurology, Ghent University Hospital, Ghent, Belgium
2 shared publications Arlène Ndayisenga
Department of Neurology King Faisal Hospital Rwanda Kigali Rwanda
1 shared publicationGeorgette Umuhoza
Department of Neurology King Faisal Hospital Rwanda Kigali Rwanda
1 shared publication- Ieme Garrez
Department of Neurology Ghent University Hospital Ghent Belgium
1 shared publication
Latest Publications
- Open Access
- 26 July 2026
- Published by Elsevier in Epilepsy & Behavior Reports
- Vol. 36, 100886
Association of depression and epilepsy in rural northern Rwanda: a prospective longitudinal study with a patient-centered approach
- 26 July 2026
- Published by Elsevier in Epilepsy & Behavior Reports
- Vol. 36, 100886
Open AccessAssociation of depression and epilepsy in rural northern Rwanda: a prospective longitudinal study with a patient-centered approach
- Open Access
- 1 March 2024
- Published by Wiley in European Journal of Neurology
- Vol. 31 (6) , e16254
Challenges to epilepsy management in Rwandan women living with epilepsy
Background and purpose: In Rwanda, epilepsy prevalence ranges between 29‰ and 49‰. Many women living with epilepsy (WwE) are of childbearing age. Epilepsy characteristics and management, contraception, pregnancy, puerperium and stigma in WwE presenting at the neurology clinic of Ndera, Rwanda, were investigated.Methods: This prospective cross‐sectional study investigated demographics, epilepsy characteristics, treatment, contraception, folic acid use, pregnancy, puerperium and stigma in WwE aged ≥18 years. Subgroups were analysed by status of any pregnancy and time of epilepsy diagnosis relative to pregnancy, with significant differences expected.Results: During December 2020 and January 2021, a hundred WwE were enrolled (range 18–67 years). Fifty‐two women had never been pregnant, 39 women had epilepsy onset before pregnancy and nine were diagnosed after pregnancy. No significant differences in age, marital status or occupation were observed. Contraception was used by 27%, of whom 50% were taking enzyme‐inducing anti‐epileptic medication. Valproate was used by 46% of WwE of reproductive age. Thirty‐nine women with epilepsy onset before pregnancy reported 91 pregnancies, with 14% spontaneous abortions. None used folic acid before conception, and 59% only during pregnancy. Five of 78 newborns were preterm. No offspring had major congenital malformations. Nearly 25% of WwE were not compliant with their anti‐epileptic medication schedule during pregnancy or breastfeeding. Internalized stigma was observed in more than 60%. Up to 25% had been discriminated against at school or work.Conclusion: A comprehensive strategy considering the reproductive health and societal challenges of WwE is needed to drive optimal epilepsy management, reproductive health outcomes and societal inclusion.
- 1 March 2024
- Published by Wiley in European Journal of Neurology
- Vol. 31 (6) , e16254
Open AccessChallenges to epilepsy management in Rwandan women living with epilepsy
Background and purpose: In Rwanda, epilepsy prevalence ranges between 29‰ and 49‰. Many women living with epilepsy (WwE) are of childbearing age. Epilepsy characteristics and management, contraception, pregnancy, puerperium and stigma in WwE presenting at the neurology clinic of Ndera, Rwanda, were investigated.Methods: This prospective cross‐sectional study investigated demographics, epilepsy characteristics, treatment, contraception, folic acid use, pregnancy, puerperium and stigma in WwE aged ≥18 years. Subgroups were analysed by status of any pregnancy and time of epilepsy diagnosis relative to pregnancy, with significant differences expected.Results: During December 2020 and January 2021, a hundred WwE were enrolled (range 18–67 years). Fifty‐two women had never been pregnant, 39 women had epilepsy onset before pregnancy and nine were diagnosed after pregnancy. No significant differences in age, marital status or occupation were observed. Contraception was used by 27%, of whom 50% were taking enzyme‐inducing anti‐epileptic medication. Valproate was used by 46% of WwE of reproductive age. Thirty‐nine women with epilepsy onset before pregnancy reported 91 pregnancies, with 14% spontaneous abortions. None used folic acid before conception, and 59% only during pregnancy. Five of 78 newborns were preterm. No offspring had major congenital malformations. Nearly 25% of WwE were not compliant with their anti‐epileptic medication schedule during pregnancy or breastfeeding. Internalized stigma was observed in more than 60%. Up to 25% had been discriminated against at school or work.Conclusion: A comprehensive strategy considering the reproductive health and societal challenges of WwE is needed to drive optimal epilepsy management, reproductive health outcomes and societal inclusion.